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ABSTRACT 
CALCULATION OF BNCT DOSIMETRY FOR BRAIN CANCER BASED ON KARTINI 
RESEARCH REACTOR USING PHITS CODE. Cancer is a dangerous disease caused by the growth 
of a mass of cells that are unnatural and uncontrollable. Glioblastoma, also called as glioblastoma 
multiforme (GBM), is one of dangerous brain cancer. The dismal prognosis associated with glioblastoma 
is attributable not only to its aggressive and infiltrative behavior, but also to its location typically deep in 
the parenchyma of the brain. In resolving this chalenge, the BNCT method can be a solution. This study 
aims to calculate BNCT dosimetry in different of cancer positions and irradiation geometries using 
PHITS code. The results show that the deeper the cancers target at brain the slower the total absorbed 
dose rate of cancer target. It takes a longer treatment time. Based on the treatment time and total absorbed 
dose rate of cancer target, the TOP irradiation geometry is an appropriate choice in treating the cancer 
target in this case. To achieve the histopathological cure of GBM at the primary site, the absorbed dose of 
brain was calculated to be 1.07 Gy and 1.64 Gy for the LLAT and PA irradiation geometry, respectively. 
While, for cancer position of 3 cm, 5 cm, 7.15 cm, 9 cm, and 11 cm, the absorbed dose of brain is 0.25 Gy, 
0.48 Gy, 0.85 Gy, 1.33 Gy, and 2.01 Gy, respectively. In addition to the stochastic effect, it was found 
also deterministic effects that may be produced such as cataracts. 
Keywords: BNCT dosimetry; GBM; brain cancer cases; PHITS; MIRD phantom 
ABSTRAK 
PERHITUNGAN DOSIMETRI BNCT PADA KANKER OTAK BERBASIS REAKTOR RISET 
KARTINI MENGGUNAKAN PROGRAM PHITS. Kanker merupakansalahsatu penyakit berbahaya 
yang diakibatkan oleh tumbuhnya sekumpulan massa sel-sel yang tidak wajar dan tidak terkendali. Salah 
satu penyakit kanker otak yang berbahaya adalah Glioblastoma atau yang biasa disebut Glioblastoma 
Multiforme (GBM). Prognosis suram terkait dengan GBM tidak hanya untuk perilaku agresif dan 
infiltrasi, tetapi juga terhadaplokasi yang jauh di dalam parenkim otak. Untuk menjawab hal tersebut, 
Boron Neutron Capture Therapy (BNCT) dapat menjadi solusi. Penilitian ini bertujuan untuk menghitung 
dosimetri BNCT dalam berbagai posisikan kerdan geometri penyinaran dengan menggunakan program 
PHITS. Hasil perhitungan menunjukkan bahwa semakin dalam target kanker di otak maka semakin kecil 
total laju dosis serap dari target kanker. Semakin dalam target kanker di otak dibutuhkan waktu 
pengobatan yang semakin lama. Berdasarkan waktu pengobatan dan laju dosis serap dari target kanker, 
bidang penyinaran TOP merupakan pilihan yang tepat dalam mengobati target kanker dalam kasus ini. 
Untuk mencapai penyembuhan GBM secara histopatologis di lokasi utama, dosis serap dari otak 
dihitung berturut-turut sebesar 1,07 Gy dan 1,64 Gy untuk bidang penyinaran LLAT dan PA. Sedangkan, 
untuk posisi kanker 3 cm, 5 cm, 7,15 cm, 9 cm, dan 11 cm, berturut-turut dosis serap dari otak adalah 
0,25 Gy, 0,48 Gy, 0,85 Gy, 1,33 Gy, and 2,01 Gy. Selain adanya efek stokastik, ditemukan juga efek 
deterministik yang mungkin dihasilkan seperti katarak. 
 
Kata kunci: Dosimetri BNCT, GBM, kasuskankerotak, geometripenyinaran, posisikanker, ORNLMIRD 
phantom. 
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INTRODUCTION 
Cancer is a dangerous disease caused by the growth of a mass of cells that is unnatural and 
uncontrollable. According to the World Health Organization (WHO), approximately 8.2 million 
people die annually from cancer or an estimated 13% of all deaths worldwide [1]. In Indonesia, the 
GLOBOCAN estimated in 2012, for all ages and both sexes, the numbers of incidence and 
mortality of brain cancer reached 3402 and 4902 [2], respectively. According to that, Indonesia 
occupied the first rank in the Southeastern Asia. Glioblastoma, also called as glioblastoma 
multiforme (GBM), is one of dangerous brain cancer. GBM is a group of gliomas grade IV 
according to the WHO classification based on the increasing degree of anaplasia and 
aggressiveness [3]. Most studies reported that the survival of patients with GBM is quite short as 
compared with anaplastic astrocytoma and low-grade gliomas [4]. The dismal prognosis associated 
with glioblastoma is attributable not only to its aggressive and infiltrative behavior, but also to its 
location typically deep in the parenchyma of the brain [5]. Location GBM generally located in 
supratentorial areas such as frontal, temporal, parietal and occipital lobes [6,7]. The median overall 
survival of GBM patients with a deep location was 10 months and 24 months for GBM patients 
with superficial location [8]. It has been treated with various methods such as radiotherapy, 
chemotherapy, and surgery. However, the prognosis of GBM patients remain poor, median overall 
survival (OS) reached 11 months, and the 1-and 2 years OS rates were 45.9% and 7.7%, 
respectively. Therefore, the need for more effective novel treatments for this disease is urgently 
needed [9]. In resolving this challenge, Boron Neutron Capture Therapy (BNCT) can be a solution. 
Several countries have conducted research on BNCT as one of the GBM therapy types such as 
Japan, Finland, Taiwan, Germany, United States, Sweden, and Czech Republic [10]. It was found 
in the experience of BNCT clinical trials in Japan that for newly diagnosed GBM cases, median 
overall survival (OS) reached 25.7 months, and the 1- and 2-year OS rates were 85.7 % and 45.5 %, 
respectively [11]. Therefore, treatment for GBM patients with BNCT showed promising survival 
benefits. BNCT is a cancer treatment method designed to be selective in destroying cancer cells and 
saving healthy tissue cells [12]. This method is based on the irradiation of neutrons to cancer cells 
containing 10B compound [13]. It causes fission reaction of 7Li nuclei and alpha particles, where 
the linear energy transfers (LETs) value are 163 keV/µm and 210 keV/µm, respectively [14]. Both 
of these particles have a high-LET as well as a short range of about one cell diameter resulting in a 
lethal dose only on cancer cells or tumors [15]. It is known as a boron dose, which is the main dose 
delivered to tumor cells or cancer. In addition to the boron dose, other major dose components such 
as nitrogen doses, gamma doses, and neutron doses are considered in the calculation of BNCT 
dosimetry [16].  
BNCT-related research based on the Monte Carlo simulation has been done in recent years 
for brain cancer cases. In 2012, Rasouli and Masoudi used Beam Shaping Assembly (BSA) 
optimization design results to show that the weighted dose rate of the tumor target for a depth of 5.2 
cm is 0.0372 Gy(w)/s [17]. In 2013, Herrera et al., showed that the minimum weighted dose rate 
delivered to the clinical target volume (CTV) was higher than 0.025 Gy(w)/s for the brain tumor 
(GBM) [18].  In 2014, Capoulat et al., investigated the reaction produced by 9Be(d, n)10B as a 
neutron source for BNCT. It was found that the maximum weighted dose rate of brain tumor for a 
depth of 4.8 cm was 0.0412 Gy(w)/s [19]. While in 2015, Brandão and Campos showed that the 
weighted dose rate of brain tumors was 0.0167 Gy(w)/s. It was obtained by combining 252Cf 
brachytherapy and BNCT [20]. In 2016, Hang et al., designed BSA to provide high epithermal 
neutron flux based on the D-T neutron generator. It was found that the weighted dose rate of brain 
tumors at a depth of 6.75 cm was 0.022 Gy(w)/s [21]. In 2017, Hsieh et al., used BSA design based 
on a DD neutron generator to show that the weighted dose rate of brain tumors at a depth of 3 cm is 
0.0196 Gy(w)/s [22]. This study aims to calculate BNCT dosimetry in different of cancer positions 
and irradiation geometries using the PHITS code. The PHITS code has been used for research 
related to BNCT [23, 24]. It can be used to evaluate the absorbed dose to each organ within the 
reference phantoms [25]. 
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MATERIAL AND METHODS 
Beam source  
The beam source was obtained from the design of collimator in the radial piercing beam port 
of Kartini Reactor for BNCT [26]. It was operated at 100 kW. The beam source is made in the form 
of a circle with a radius of 1 cm. It consists of four source components, namely thermal neutron, 
epithermal neutron, fast neutron, and primary gamma-ray. The distance between the beam source 
and the phantom surface was set as 10 cm. Table 1 lists the source strength of each of the four 
components of the beam source for Kartini Reactor operated at 100 kW.  
Table 1. Source strengths of the different components of the Kartini Reactor beam source. 
Patient model  
In this study, GBM patient was defined as ORNL MIRD phantom [27] that was simulated in 
the PHITS code. The ORNL MIRD phantom has been used for BNCT-related research [28,29]. It 
was created by researchers at Hanyang University in Korea. The ORNL MIRD phantom is ready 
for use for BNCT dosimetry calculations and it is available at the Los Alamos National Laboratory 
database [30] and the Computational Medical Physics Working Group [31]. Three types of material 
compositions, namely, soft tissue, lung, and bone were used in the phantom. Fig. 1 shows the 
outline of the phantom without skin made with the PHITS code in three dimensions. Cancer target 
was assumed as the clinical target volume (CTV). It was defined as a sphere with radius of 1.5 cm. 
According to the data of 22 recurrent glioma patients were treated with BNCT in Finland, the 10B 
concentration in blood in lies the range from 11 to 22 ppm, from 19 to 46 ppm in brain, and from 
44 to 93 ppm in tumor under BPA-f infusion of 290-450 mg/kg during 2 hours [32]. Therefore, the 
10B concentration in the cancer target was reasonably taken as 60 and 20 ppm for the normal organs 
assuming that the 10B concentrations in normal tissue and in blood are the same. 
 
Source particle Energy range (MeV) Beam aperture ( radius of 1 cm ) 
  
Total source strength(s-1) 
Average surface 
source strength 
(cm-2 s-1) 
Thermal neutron 0 ~ 5.00E-07 4.1409E+08 1.3181E+08 
Epithermal neutron 5.00E-07 ~ 1.00E-02 3.0527E+08 9.7170E+07 
Fast neutron 1.00E-02 ~ 1.80E+01 3.0184E+08 9.6080E+07 
Total neutron 0 ~ 1.80 E+01 1.0212E+09 3.2506E+08 
Primary gamma 0 ~ 1.80E+01 3.0355E+08 9.6622E+07 
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Figure 1.Outline and irradiation geometries of the ORNL MIRD phantom. 
Calculation of BNCT dosimetry  
The Monte Carlo code PHITS version 2.81[33] was applied to calculate BNCT dosimetry 
for clinical cases. The clinical cases that were selected to cover the study of brain cancer (GBM) are 
presented. This set of cases included superficial and deep cancer. In addition, the selection of 
appropriate irradiation geometry for the treatment of brain cancer was also involved. Therefore, the 
simulation in this study was conducted in two stages. In the first stage, it was performed to 
investigate the effect of different cancer positions toward the total absorbed dose rates of cancer 
target and some representative organs. Note that in the first stage, the TOP irradiation geometry 
was made constant. In the second stage, the simulation was performed to investigate the effect of 
different irradiation geometries toward the total absorbed dose rates of cancer target and some 
representative organs. Note that in the second stage, the cancer position of 7.15 cm was made 
constant. The cancer positions and irradiation geometry is shown in Table 2.  
Table 2.Different of cancer positions and irradiation geometries. 
Cancer positiona 
(cm)  
Irradiation 
geometry  
3  TOPb 
5  AP  
7.15c LLAT  
8  -  
11   - 
aThe cancer position is the depth of cancer in the brain. It is defined as the distance between the 
skin and the center of mass of the tumor.  
bThe irradiation geometry is made constant in the first stage.  
cThe cancer position is made constant in the second stage. It defines the center of mass of the 
tumor.  
The absorbed dose rate due to the neutron, gamma, 14N (n, p)14C reaction and 10B (n, α)7Li reaction 
were determined separately. The absorbed dose due to 14N (n, p)14C and 10B (n, α)7Li reaction were 
determined using the [T-DEPOSIT] tally. It is used to calculate energy loss of charged particles and 
nuclei. While, for the absorbed neutron and gamma dose, they were determined using the [T-
P-ISSN: 1411–240X E-ISSN: 2527-9963 
Nomor: 632/AU3/P2MI-LIPI/03/2015 
(Masa Berlaku Akreditasi s/d Mei 2018)	
Calculation of BNCT Dosimetry for … 
(Suhendra) 
 
 163 
 
TRACK] tally and [MULTIPLIER] section considering kerma coefficients in the Dosimetry 
System 2002 (DS02) [34]. Note that the gamma dose is the sum of the secondary gamma dose 
which is generated of the 1H (n, γ)2H reaction and the primary gamma dose which is generated 
from primary gamma-ray sources.  
Table 3.Relative- and compound biological effectiveness of different dose components for use in the 
calculation of BNCT dosimetry. 
Dose component  RBE/CBE  
Boron dose (DB)  CBE=3.8:1.3 for 
cancer:normal 
organ  
Nitrogen dose (DN)  RBE= 3.2  
Gamma dose (Dγ)  RBE= 1  
Neutron dose(Dnf)  RBE= 3.2  
 
In term of BNCT, the weighted dose or commonly known as the total biologically weighted 
dose, is defined as [35]:  
 D! = CBE x D!  +  RBE x D!" +  RBE x D! +  RBE x D! (1) 
 
Where Dnf, Dγ, DB dan DN are the absorbed dose due to neutron, gamma, 10B(n, α)7Li 
reaction, and 14N(n, p)14C reaction, respectively. The values of Relative Biological Effectiveness 
(RBE) and Compound Biological Effect (CBE) are shown in Table 3[36,37,18]. RBE is 
comparison of absorbed doses of radiation reference sources with test radiation that produce the 
same biological effect, whereas CBE is a factor of the biological effect used on boron carrier 
compound [38,39]. To illustrate the difference of the absorbed and weighted doses, the letter W in 
parenthesis is added to the symbol Gy writing one space between the symbol and the additional 
specification for the weighted dose (Gy (w) [40].  
RESULTS AND DISCUSSION 
The results of BNCT dosimetry calculations obtained in the first and second stages are 
shown in Table 4. In the first stage, Table 4 lists the total absorbed dose rates of cancer target and 
some representative organs for different cancer positions. Note that in the first stage, the TOP 
irradiation geometry is made constant. In the second stage, Table 4 also lists the total absorbed dose 
rates of cancer target and some representative organs for different irradiation geometry. Note that in 
the second stage, the cancer position of 7.15 cm is constant. In addition, the total weighted dose 
rates of cancer targets and some representative organs are included in Table 4. As shown in Table 
4, the total weighted dose rate is greater than the total absorbed rate by a factor of 1.42-3. 
Table 4.The total absorbed and weighted dose of cancer target and some representative organ 
Cancer Positiona (cm) 3 5 7.15b   9 
Total 
absorbed 
dose (Gy) 
Cancer 2.87E-03 1.73E-03 1.08E-03 (9.12E-04)c (6.34E-04)d 7.54E-04 
Brain 4.84E-05 5.43 E-05 5.78E-05 (5.93E-05) (6.02E-05) 5.95E-05 
Cranium 3.29E-05 3.30E-05 3.31E-05 (3.33E-05) (3.28E-05) 3.31E-05 
Head and 
Neck Skin 
1.41E-05 1.41E-05 1.41E-05 (1.46E-05) (1.43E-05) 1.41E-05 
Thyroid 2.02E-06 2.05E-06 1.97E-06 (5.24E-06) (3.89E-06) 2.03E-06 
Weighted 
dose rate 
(Gy) 
Cancer 8.62E-03 4.96E-03 2.98E-03 (2.44E-03)c (1.61E-03)d 1.97E-03 
Brain 1.18E-04 1.35E-04 1.45E-04 (1.45E-04) (1.55E-04) 1.50E-04 
Cranium 7.99E-05 8.02E-05 8.03E-05 (8.06E-05) (8.05E-05) 8.02E-05 
Head and 
Neck Skin 
3.59E-05 3.59E-05 3.59E-05 (3.68E-05) (3.66E-05) 3.59E-05 
Thyroid 4.02E-06 4.10E-06 3.90E-06 (7.43E-06) (3.78E-06) 4.07E-06 
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aThe cancer position is the depth of cancer in the brain. It is defined as the distance between 
the skin and the center of mass of the tumor, bThe center of mass of the tumor, cLLAT irradiation 
geometry, dPA irradiation geometry 
As shown in Table 4, for the first stage, the total absorbed dose rate of target cancer is 
significantly different at each cancer position. In other words, the deeper the cancer target at brain 
means the slower the total absorbed dose rate of cancer target. Table 4 also shows that the total 
absorbed dose rate of some representative organs such as cranium, head and neck skin, and thyroid 
are not significantly different in each cancer position. Meanwhile, the total absorbed dose rate of 
brain is significantly different in each cancer position. Seen in Table 4, the total absorbed dose rate 
of brain was increased in each cancer position. As expected, the total absorbed dose rate of target 
cancer is greater than the total absorbed dose rate of some representative organs for different cancer 
positions. For the second stage, the total absorbed dose rate of cancer target is significantly different 
in the irradiation geometry. The total absorbed dose rate of target cancer for the TOP irradiation 
geometry is greater than the total absorbed dose rate of target cancer for the LLAT and PA 
irradiation geometry. Regarding the average absorbed dose rate of brain and skin (skin of head and 
neck) as shown in Table 4, the TOP irradiation geometry is smaller than the LLAT and PA 
irradiation geometry. For the total absorbed dose rate of cranium, the LLAT irradiation geometry is 
greater than the TOP and PA irradiation geometry. For the total absorbed dose rate of thyroid, the 
TOP irradiation geometry is greater than the LLAT and PA irradiation geometry. However, the 
TOP irradiation geometry is an appropriate choice in treating the cancer target in this case. To 
achieve the histopathological cure of GBM at the primary site, the optimal minimal dose to the 
CTV was 44 Gy(w) [41]. Based on it and from the data in Table 4, the treatment time has been 
calculated for the first and second stages. These results are presented in Table 5.  
Table 5. The treatment time for different of cancer positions and irradiation geometries 
Cancer positiona (cm) Treatment time (hour) 
3 1.42 
5 2.46 
7.15b 4.11 (5.01)c (7.59)d 
9 6.22 
11 9.19 
 
aThe cancer position is the depth of cancer in the brain. It is defined as the distance between 
the skin and the center of mass of the tumor. bThe center of mass of the tumor cLLAT irradiation 
geometry dPA irradiation geometry  
In the first stage, for cancer position of 3 cm, 5 cm, 7.15 cm, 9 cm, and 11 cm, the treatment 
time are 1.42 hours, 2.46 hours, 4.11 hours, 6.22 hours, and 9.19 hours, respectively. In the second 
stage, the treatment time is 5.01 hours and 1.64 hours for the LLAT and PA irradiation geometry, 
respectively. As shown in Table 5, the cancer target is getting deeper, thus requires a longer 
treatment time. Table 5 also shows that treatment time for the TOP irradiation geometry is faster 
than treatment time for the LLAT and PA irradiation geometry. From the data in Table 4 and the 
treatment time shown in Table 5, the absorbed doses of some representative organ has been 
calculated. These results are presented in Table 6. In addition, the total weighted dose of some 
representative organ is included in Table 6. As shown in Table 6, in the first stage, for cancer 
position of 3 cm, 5 cm, 7.15 cm, 9 cm, and 11 cm, the absorbed dose of brain is 0.25 Gy, 0.48 Gy, 
0.85 Gy, 1.33 Gy, and 2.01 Gy, respectively. In the second stage, the absorbed doses of brain are 
1.07 Gy and 1.64 Gy for the LLAT and PA irradiation geometry, respectively.  
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Table 6. The total absorbed and weighted dose of cancer target and some representative organ 
Cancer Positiona (cm)  3 5 7.15b   9 11 
Total absorbed dose (Gy) 
Brain 0.25 0.48 0.85 (1.07)c (1.64)d 1.33 2.01 
Cranium 0.17 0.29 0.49 0.60 (0.90) 0.74 1.09 
Head and Neck Skin 0.07 0.13 0.21 0.26 (0.39) 0.32 0.47 
Thyroid 0.01 0.02 0.03 0.01 (0.01) 0.05 0.07 
Weighted dose rate (Gy) Brain 0.60 1.20 2.15 2.70 (4.23) 3.37 5.09 
Cranium 0.41 0.71 1.19 1.45 (2.20) 1.79 2.65 
Head and Neck Skin 0.18 0.32 0.53 0.66 (1.00) 0.80 1.19 
Thyroid 0.02 0.04 0.06 0.01 (0.02) 0.09 0.14 
 
aThe cancer position is the depth of cancer in the brain. It is defined as the distance between 
the skin and the center of mass of the tumor, bThe center of mass of the tumor, cLLAT irradiation 
geometry, dPA irradiation geometry 
In addition to the stochastic effect related to the calculated absorbed dose, it was also found 
the deterministic effects that cannot be ignored in Table 6. According to the International 
Commission on Radiological Protection (ICRP), Assessment of the lens of the eye, skin, and 
extremity doses and methods of protection is necessary to improve occupational protection in 
interventional and nuclear medicine procedures [42]. Although the absorbed dose of the lens of the 
eye is not calculated on the ORNL MIRD phantom, it should be comparable to the absorbed dose 
of brain. Since the threshold absorbed dose of the lens of the eye is now considered to be 0.5 
Gy[43], Cataracts may occur in GBM patients treated with therapy BNCT for cancer positions of 
7.15 cm, 9 cm, and 11 cm.  
CONCLUSION  
BNCT dosimetry in brain cancer cases has been calculated using the PHITS code. The 
results show that the deeper the cancers target at brain means the slower the total absorbed dose rate 
of cancer target. It takes a longer treatment time. Based on the treatment time and total absorbed 
dose rate of cancer target, the TOP irradiation geometry is an appropriate choice in treating the 
cancer target in this case. To achieve the histopathological cure of GBM at the primary site, the 
absorbed dose of brain was calculated to be 1.07 Gy and 1.64 Gy for the LLAT and PA irradiation 
geometry, respectively. While, for cancer position of 3 cm, 5 cm, 7.15 cm, 9 cm, and 11 cm, the 
absorbed dose of brain is 0.25 Gy, 0.48 Gy, 0.85 Gy, 1.33 Gy, and 2.01 Gy, respectively. In 
addition to the stochastic effect, it was found also deterministic effects that may be produced such 
as cataracts.  
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